TABLE 4.

Clinical manifestations of HIT induced by LMWHs.

Parameter	Value	Percentage (%)
The time from taking LMWHs to HIT diagnosed (n = 43)
<5 days	5	11.63
Enoxaparin	3	6.98
Nadroparin	1	2.33
Tinzaparin	1	2.33
5–10 days	24	55.81
Enoxaparin	13	30.23
Nadroparin	10	23.26
Bemiparin	1	2.33
>10 days	14	32.56
Enoxaparin	5	11.63
Dalteparin	4	9.30
Nadroparin	3	6.98
Bemiparin	1	2.33
Tinzaparin	1	2.33
Clinical manifestations of HIT (n = 43)
Thrombus	39	90.70
Skin lesions	15	34.88
Dyspnea	13	30.23
Hemorrhage	9	20.93
Limb necrosis	5	11.63
Cerebral infarction	5	11.63
Heart failure	5	11.63
Acute renal failure	2	4.65
Shock	1	2.33
Fever	1	2.33
Peak PLT at HIT diagnosis
PLT count (10^9/L) (n = 40)
<10	1	2.50
Nadroparin	1	2.50
10–19	3	7.50
Enoxaparin	1	2.50
Dalteparin	1	2.50
Nadroparin	1	2.50
20–49	13	32.50
Enoxaparin	8	20.00
Nadroparin	2	5.00
Dalteparin	1	2.50
Bemiparin	1	2.50
Tinzaparin	1	2.50
50–100	14	35.00
Enoxaparin	7	17.50
Nadroparin	5	12.50
Dalteparin	1	2.50
Bemiparin	1	2.50
>100	9	22.50
Enoxaparin	5	12.50
Nadroparin	2	5.00
Dalteparin	1	2.50
Tinzaparin	1	2.50
Percentage of PLT decrease (n = 37)
<30%	1	2.70
Tinzaparin	1	2.70
30%–50%	3	8.11
Enoxaparin	2	5.41
Nadroparin	1	2.70
>50%	33	89.19
Enoxaparin	19	51.35
Nadroparin	8	21.62
Dalteparin	3	8.11
Bemiparin	2	5.41
Tinzaparin	1	2.70
Anti-PF4 antibody(n = 36)
Positive	36	100.00
Enoxaparin	17	47.22
Nadroparin	12	33.33
Dalteparin	4	11.11
Bemiparin	2	5.56
Tinzaparin	1	2.78
Warkentin 4T score (n = 21)
0–3	0	0.00
4–5	3	14.29
Dalteparin	2	9.52
Enoxaparin	1	4.76
6–8	18	85.71
Nadroparin	9	42.86
Enoxaparin	6	28.57
Bemiparin	2	9.52
Tinzaparin	1	4.76
D-Dimer elevated (n = 11)	5	45.45
Abnormal liver and kidney functions (n = 8)	5	62.50